Page 205 - 2020_07-Haematologica-web

Lenalidomide-based regimens in elderly MM
12. Franssen LE, Nijhof IS, Bjorklund CC, et al. Lenalidomide combined with low-dose cyclophosphamide and prednisone modu- lates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget. 2018;9(74):34009- 34021.
13. Nakagawa M, Terashima T, D’yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demar- gination of intravascular granulocytes. Circulation. 1998;98(21):2307-2313.
14. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142- 152.
15. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in com- bination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9): 1801-1809.
16. Facon T, Hulin C, Dimopoulos MA, et al. A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low- dose dexamethasone on the FIRST trial.
Blood. 2015;126(23). Abstract #4239 [ASH
2015 57th Meeting].
17. Facon T, Dimopoulos MA, Dispenzieri A,
et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treat- ment for multiple myeloma. Blood. 2018;131(3):301-310.
immediate autologous stem cell transplant (ASCT). Blood. 2018;132(Suppl 1). Abstract #1992 [ASH 2018 60th Meeting].
21. Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, mel- phalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-
18. Facon T, Kumar SK, Plesner T, et al. Phase 3 528.
randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed mul- tiple myeloma (NDMM) ineligible for transplant (MAIA). Blood. 2018;132(Suppl 1). Abstract #LBA-2 [ASH 2018 60th Meeting].
19. Larocca A, Salvini M, De Paoli L, et al. Efficacy and feasibility of dose/schedule- adjusted Rd-R vs. continuous Rd in elderly and intermediate-fit newly diagnosed mul- tiple myeloma (NDMM) patients: RV-MM- PI-0752 phase III randomized study. Blood. 2018;132(Suppl 1). Abstract #305 [ASH 2018 60th Meeting].
20. Durie BG, Hoering A, Sexton R, et al. Longer term follow up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for
22. Ocio EM, Otero PR, Bringhen S, et al. Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexametha- sone (VRd) in patients with newly diag- nosed multiple myeloma (NDMM) non- eligible for transplant. Blood. 2018;132(Suppl 1). Abstract #595 [ASH 2018 60th Meeting].
23. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dex- amethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
24. Dimopoulos MA, Mateos M-V, Cavo M, et al. One-year update of a phase 3 random- ized study of daratumumab plus borte- zomib, melphalan, and prednisone (D- VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed mul- tiple myeloma (NDMM): Alcyone. Blood. 2018;132(Suppl 1). Abstract #156 (ASH 2018 60th Meeting].
haematologica | 2020; 105(7)
1947